

CLAIMS

1. An antibody or antigen-binding fragment thereof, comprising:
 - a) a heavy chain variable region comprising CDR1, CDR2 and CDR3 sequences as set forth in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3, respectively; and a light chain variable region comprising CDR1, CDR2 and CDR3 sequences as set forth in SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.
2. The antibody or antigen-binding fragment thereof of claim 1, comprising:
 - a) a heavy chain variable region comprising SEQ ID NO: 7 and a light chain variable region comprising SEQ ID NO: 8.
3. The antibody or antigen-binding fragment thereof of claim 1, further comprising an immunoglobulin constant region, optionally a constant region of human Ig, or optionally a constant region of human IgG.
4. The antibody or antigen-binding fragment thereof of claim 1, which is a Fab, a Fab', a F(ab')₂, a Fd, an Fv fragment, a disulfide stabilized Fv fragment (dsFv), a (dsFv)₂, a single-chain antibody molecule (scFv), a camelized single domain antibody, a nanobody, a domain antibody, and a bivalent domain antibody.
5. The antibody or antigen-binding fragment thereof of claim 1, wherein the antibody or antigen-binding fragment is linked to one or more conjugates, optionally, wherein the conjugate is covalently attached either directly or via a linker.
6. A pharmaceutical composition comprising the antibody or antigen-binding fragment thereof of claim 1, and a pharmaceutically acceptable carrier.
7. An isolated polynucleotide encoding the antibody or antigen-binding fragment thereof of claim 1.
8. A vector comprising the isolated polynucleotide of claim 7.

9. A host cell comprising the vector of claim 8.

10. The antibody or antigen-binding fragment thereof of claim 1 for use in treating a disease or condition in a subject that would benefit from modulation of CD276 activity, wherein a therapeutically effective amount of the antibody or antigen-binding fragment thereof is to be administered to the subject.

11. The antibody or antigen-binding fragment thereof for use of claim 10, wherein the disease or condition is cancer, adaptive immune disease, autoimmune disease, inflammatory disease, or infectious disease.

12. The antibody or antigen-binding fragment thereof of claim 1 for use in modulating CD276 activity in a CD276-expressing cell, wherein the CD276-expressing cell is to be exposed to the antibody or antigen-binding fragment thereof.